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Abstract
Background: In2009,a novel influenza virus (2009 pandemic influenza A (H1N1) virus (pH1N1)) caused significant disease in the
United States. Most states, including Florida, experienced a large fall wave of disease from September through November, after
whichdiseaseactivitydecreasedsubstantially.WedeterminedtheprevalenceofantibodiesduetothepH1N1virusinFloridaafter
influenza activity had peaked and estimated the proportion of the population infected with pH1N1 virus during the pandemic.
Methods: During November-December 2009, we collected leftover serum from a blood bank, a pediatric children’s hospital
and a pediatric outpatient clinic in Tampa Bay Florida. Serum was tested for pH1N1 virus antibodies using the
hemagglutination-inhibition (HI) assay. HI titers $40 were considered seropositive. We adjusted seroprevalence results to
account for previously established HI assay specificity and sensitivity and employed a simple statistical model to estimate
the proportion of seropositivity due to pH1N1 virus infection and vaccination.
Results: During the study time period, the overall seroprevalence in Tampa Bay, Florida was 25%, increasing to 30% after
adjusting for HI assay sensitivity and specificity. We estimated that 5.9% of the population had vaccine-induced
seropositivity while 25% had seropositivity secondary to pH1N1 virus infection. The highest cumulative incidence of pH1N1
virus infection was among children aged 5–17 years (53%) and young adults aged 18–24 years (47%), while adults aged $50
years had the lowest cumulative incidence (11–13%) of pH1N1 virus infection.
Conclusions: After the peak of the fall wave of the pandemic, an estimated one quarter of the Tampa Bay population had
been infected with the pH1N1 virus. Consistent with epidemiologic trends observed during the pandemic, the highest
burdens of disease were among school-aged children and young adults.
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Introduction
The 2009 pandemic influenza A (H1N1) virus (pH1N1) was first
identified in April 2009 and caused widespread illness in the
United States and around the world [1]. The Centers for Disease
Control and Prevention (CDC) estimated that during the
pandemic, 14–29% of the US population had a clinical case of
influenza [2]. However this estimate excluded subclinical cases
which may have accounted for 24–36% of all infections [3,4,5,6].
During the 2009 pandemic, Florida employed a surveillance
system that tracked the percentage of Emergency Department (ED)
visits for influenza-like illness (ILI) throughout the state. According
to surveillance data, Tampa Bay experienced a gradual increase in
influenza activity in the spring and summer of 2009, followed by a
large fall wave of influenza activity that peaked in late October and
decreased steadily thereafter (Figure 1). Estimating the total number
of pH1N1 virus infections in Tampa Bay that were acquired during
this time period presented several challenges. Existing disease
surveillance likely provided an underestimate of the true proportion
ofindividualsinfected,duetoitspassivenature.Inaddition,patients
with laboratory-confirmed infections represented only a fraction of
the total burden, as not all infected persons sought medical care,
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29301were tested for influenza, or tested positive for influenza virus
infection due to the timing or quality of the specimen collected.
Serosurveys, which estimate the prevalence of antibodies to a
specific pathogen, can be a valuable tool in determining the
proportion of the population infected with a novel virus. Unlike
most influenza surveillance, which relies on presentation of clinical
illness, serosurveys capture persons that experienced symptomatic
or asymptomatic illness, and can provide information on total
infections which may be underestimated with traditional surveil-
lance methodologies. However, serosurveys are limited by the
sensitivity and specificity of the assay employed to detect antibody
titers [7] and by the presence of cross reactive antibodies from prior
exposure to antigenically related viruses [8,9]. Furthermore, assays
to detect antibody against influenza viruses cannot distinguish
between antibody elicited by virus infection versus vaccination.
To date, one published study has reported on the prevalence of
pH1N1 antibodies among residents in one region of the United
States [10]. Additional studies performed throughout the world
have also been published, adding to the body of literature
describing the disease burden of the pH1N1 pandemic
[9,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. The objective of
our study was to determine the seroprevalence of pH1N1
antibodies among residents of Tampa Bay, Florida after the peak
of the fall wave and prior to widespread vaccination.
Methods
In November and December 2009, after pH1N1 virus activity
in Tampa Bay had peaked (Figure 1), we collected a convenience
sample of de-identified, leftover serum specimens (initially drawn
for other laboratory testing) from residents of Pasco, Hillsborough,
Manatee and Pinellas counties in Tampa Bay, Florida.
We sought to collect 160 specimens from each of six age groups:
,5 years, 5–17 years, 18–24 years, 25–49 years, 50–64 years and
$65 years. Infants less than 6 months were excluded due to the
potential for maternal antibody transmission. The required sample
size was calculated using relative standard error measurements.
We estimated that the lowest seroprevalence for all groups would
be among adults aged $65 years. At the time of the serosurvey, we
estimated that 15% of this age group would be seropositive,
requiring a sample size of approximately 160 to maintain a relative
standard error less than 20%. We were able to collect at least 160
samples from all ages groups except for children aged ,5 years for
which we were only able to collect 60 samples. We estimated that
the seroprevalence among this age group would be high (30%),
and therefore despite the small sample size, would meet the
relative standard error criteria of less than 20%.
This study was proposed to the Florida Department of Health
Institutional Review Board (IRB) and Centers for Disease Control
and Prevention (CDC) IRB who considered the investigation as
public health response, and therefore not subject to IRB review
and approval.
Leftover serum specimens for Tampa Bay residents aged $16
years were collected from a large blood bank testing facility during
a 4-day period from November 30 -December 3, 2009 (Figure 1).
For residents aged ,16 years, leftover specimens were collected
from a children’s medical center and an outpatient pediatric clinic
from November 14 to December 31, 2009. The majority of
specimens collected from the children’s medical center had been
collected for allergy and immunology testing. Leftover specimens
Figure 1. Percentage of Emergency Department (ED) visits for influenza-like illness (ILI)*, Florida Electronic Surveillance System for
the Early Notification of Community-based Epidemic (ESSENCE), and time period of serum collection for seroprevalence survey —
Tampa Bay Florida**— April 2009–January 2010. *Influenza-like illness (ILI) is defined as fever ($100uF) accompanied by either cough or sore
throat **Includes Hillsborough, Manatee, Pinellas and Pasco counties.
doi:10.1371/journal.pone.0029301.g001
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outpatient testing.
Antibodies against pH1N1 virus were detected by the
hemagglutination-inhibition (HI) assay as previously described
using A/California/07/2009 virus [25,26]. All specimens were
tested in triplicate. Specimens with a geometric mean HI titer $40
were considered to be seropositive. Total seroprevalence results
were age-standardized based on Tampa Bay population estimates
from the American Community Survey. Previous studies have
shown that an HI titer $40 is associated with a $ 50% reduced
risk of contracting seasonal influenza virus infection among
susceptible persons [27,28].
Using sera from patients with pH1N1 laboratory-confirmed
infectionsandnon-exposedUnited Statesresidents,apreviousstudy
determined that a threshold HI titer $40 yielded a sensitivity of
75% and specificity of 97% in determining previous infection with
the pH1N1 virus among persons ,60 years of age [7]; specificity
wasshown to decrease to94%among persons .60 years of age. We
adjusted the overall seroprevalence results to account for both the
sensitivity and specificity of the HI assay, terming the resultant
estimate the assay-adjusted seroprevalence (Appendix S1).
Because serology cannot differentiate between antibodies
produced by virus infection and response to vaccination, we
developed a simple statistical model to estimate the proportion of
seropositive results due to pH1N1 vaccination coverage (i.e.,
vaccine-induced seropositivity ) (Appendix S2). Monthly vaccina-
tion coverage estimates for the state of Florida during November
and December 2009 were calculated based on combined
Behavioral Risk Factors Surveillance System (BRFSS) and
National 2009 H1N1 Flu Survey (NHFS) data [29,30,31,32]. In
the model we used vaccination coverage estimates, vaccine
immunogenicity estimates from the literature [33,34,35], and an
estimate of the proportion infected prior to vaccination to estimate
the proportion with vaccine-induced seropositivity not infected
prior to vaccination. To estimate the proportion of the population
infected with the pH1N1 virus prior to the serosurvey, we
subtracted this proportion from the seroprevalence estimate.
Results
Overall, 27% of the study sample had pH1N1 antibody titers
$40 with an age-standardized seroprevalence of 25% (Table 1). A
cumulative reverse curve demonstrating the distribution of
geometric mean titres (GMT) is shown in Figure 2. After adjusting
for HI assay sensitivity and specificity, the overall assay-adjusted
seroprevalence was 30%. The highest assay-adjusted seropreva-
lence was in children aged 5–17 years (60%) and young adults
aged 18–24 years (50%). Older adults had the lowest assay-
adjusted seroprevalance, ranging from 17–24%.
The overall BRFSS/NHFS vaccination coverage estimate for
Florida two weeks prior to the time of specimen collection was
9.0%, with the highest vaccination coverage among children aged
,5 years (17%) and school-aged children aged 5–17 years (15%)
(Table 2). Based on data from previously published studies, we
assumed vaccine immunogenicity ranged from 60% in children
aged ,5 years to 95% in adults aged 18–64 years [33,34,35].
Using these figures, we estimated that 5.9% of the Tampa Bay
population was seropositive due to vaccination, with the highest
proportion among children ,5 years (7.5%) and the lowest
proportion among young adults aged 18–24 years (3.1%).
Theproportion ofTampaBayresidentsthat wereestimated tobe
seropositive due to infection with pH1N1 virus after the peak of the
fall wave was 25% (Figure 3). The highest cumulative incidence of
infection with pH1N1 virus was among children aged 5–17 years
and young adults aged 18–24 years (53% and 47%, respectively).
Adults aged 50–64 years and $65 years had the lowest cumulative
incidence of infection with the pH1N1 virus (11% and 9.2%,
respectively). Applying these results to the Tampa Bay population,
approximately 700,000 of Tampa Bay’s 2.8 million residents were
infected with the pH1N1 virus and 250,000 residents had received
the pH1N1 vaccine by the end of the second wave of the pandemic.
Discussion
By December 2009, an estimated 30% of Tampa Bay’s
population had elevated levels of antibodies against the pH1N1
virus (25% from infection and 5.9% from vaccination). Our
estimates indicate that half of young adults aged 18–24 years and
more than half of school-aged children had antibodies to the
pH1N1 virus at titers of $40 at that time. Thus, the proportion of
the Tampa Bay population among these age groups that remained
susceptible to pH1N1 virus infection by December 2009 was
markedly decreased.
Table 1. Proportion of Tampa Bay population with elevated pH1N1 antibody titers and adjustment for hemagglutination
inhibition (HI) assay sensitivity and specificity by age group — Tampa Bay Florida, November-December 2009.
Age Group
Number
tested
HI titer
$20 (n)
Prevalence of
HI titer $20,
% (95% CI)
HI titer
$40 (n)
Prevalence of
HI titer $40
% (95% CI)
Assay-adjusted
1 prevalence
(HI titer $40)
% (95% CI)
,5 years 60 20 33 (21–45) 17 28 (17–40) 35 (23–47)
5–17 years 159 78 49 (41–57) 73 46 (38–54) 60 (52–67)
18–24 years 150 74 49 (41–57) 59 39 (32–47) 50 (42–58)
25–49 years 169 56 33 (26–40) 34 20 (14–26) 24 (17–30)
50–64 years 173 46 27 (20–33) 27 16 (10–21) 18 (12–23)
65+ years 165 56 34 (27–41) 29 18 (12–23) 17 (11–22)
Total
(Age-standardized )
2
876 330 36 (33–39) 239 25 (22–28) 30 (27–34)
1Seroprevalence adjusted for assay sensitivity and specificity. For children and adults aged ,65 years, assay-adjusted seroprevalence was calculated using a sensitivity
of 75% and a specificity of 97%. For adults aged $ 65 years, assay-adjusted seroprevalence was calculated using a sensitivity of 75% and a specificity of 94%.
2Total seroprevalence results were age-standardized based on Tampa Bay population estimates from the American Community Survey (includes residents of Pasco,
Hillsborough, Manatee and Pinellas counties).
doi:10.1371/journal.pone.0029301.t001
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lished studies from Pittsburgh, PA [10] and international studies
that collected sera at comparable time periods [11,13,15,16,
20,24,36]. Consistent with other studies, school-aged children
were estimated to have had the highest seroprevalance of pH1N1
antibodies [10,11,12,13,15,24]. This result coincides with the
elevated clinical attack rates of pH1N1 illness observed among
children during the pandemic and the focused vaccination
campaigns for this age group [19,37]. While pH1N1 vaccine
supplies were limited, school-aged children were targeted for
vaccination due to outbreaks of disease in settings such as schools
[38,39]. We found a similarly elevated seroprevalence among
young adults aged 18–24 years, consistent with other studies which
employed a comparable age distribution [9,12,13].
Though the availability of pH1N1 vaccine was still limited by
the time of the serosurvey (52 million doses had been distributed in
the United States by the end of November, enough to vaccinate
17% of the population), school-aged children comprised one of the
target groups for initial vaccination campaigns, and thus were
more likely to receive the vaccine earlier [39]. By two weeks prior
Figure 2. Reverse cumulative distribution curve of geometric mean HI titers for study samples, Tampa Bay, Florida – November-
December 2009.
doi:10.1371/journal.pone.0029301.g002
Table 2. Statistical model to estimate the proportion of Tampa Bay residents with vaccine-induced pH1N1 virus seropositivity in
November- December 2009.
Age Group
Vaccine coverage
estimate
1
Vaccine
immunogenicity
estimate
Proportion with
vaccine-induced
seropositivity
2
Proportion with
infection and
vaccination
3
Proportion with vaccine-induced
seropositivity not infected prior to
vaccination
4
,5 years 17% 60% 10% 2.5% 7.5%
5–17 years 15% 80% 12% 5.8% 6.4%
18–24 years 6.0% 95% 5.7% 2.6% 3.1%
25–49 years 6.0% 95% 5.7% 1.0% 4.7%
50–64 years 7.4% 95% 7.0% 0.7% 6.3%
$65 years 9.8% 85% 8.3% 0.7% 7.6%
Total 9.0% 85% 7.7% 1.7% 5.9%
1Estimated from Behavioral Risk Factors Surveillance System (BRFSS) and National 2009 H1N1 Flu Survey (NHFS) for adult vaccination through mid-November and a
weighted pediatric vaccination estimate for the two week period prior to specimen collection (November 1 – December 16, 2009).
2Estimated proportion of population with vaccine-induced seropositivity ($1:40 GMT) = (vaccine coverage) x (proportion with $1:40 seropositivity).
3Estimated proportion with pH1N1 virus infection prior to vaccination = ([assay adjusted seroprevalence] minus [estimated proportion of population with vaccine-
induced seropositivity]) x (estimated proportion of population with vaccine-induced seropositivity).
4Proportion with vaccine-induced seropositivity not infected prior to vaccination = (estimated proportion of population with vaccine-induced seropositivity) minus
(estimated proportion of population with pH1N1 virus infection prior to vaccination).
doi:10.1371/journal.pone.0029301.t002
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9% of the overall Florida population were vaccinated (Table S1).
However, even after adjusting for vaccine-induced seropositivity,
we found that a substantial proportion of school aged children
(53%) and young adults (47%) had evidence of infection with
pH1N1 virus. By May 2010, the proportion of the Florida
population that had received the pH1N1 vaccine had increased to
22% [29]. Thus, it is likely that the proportion of the Tampa Bay
population that was susceptible to the 2009 H1N1 virus at the
beginning of the 2010–2011 influenza season was lower.
Our survey has several potential limitations. First, we did not
have baseline serum specimens prior to the 2009 pandemic for
comparison and therefore were not able to test for a four-fold rise in
antibody titers or adjust for pre-existing, cross-reactive antibody
titers. Previous studies have suggested that cross-reactive antibodies
were most common among persons aged $60 years [9,11]. Second,
ourserum specimens came from blood-bankand leftover laboratory
testing; thus those sampled were not representative of the Tampa
Bay population as a whole. Third, HI titers of $40 have been used
as a threshold criteria for seropositivity by other studies and are
correlated with immunity [27,28]; however, lower antibody titers
may occur in some people with evidence of polymerase chain
reaction (PCR)-confirmed influenza infection [7]. While we did
adjust for the sensitivity and specificity of the serologic assay, we still
may have underreported the number of pH1N1 infections that
occurred by December 2009 in Tampa Bay. Finally, because we
used anonymous specimens for testing, we were not able to collect
individual-levelvaccination or symptom data. We sought to counter
part of this limitation by using vaccination estimates specific to
Florida. However, the vaccination data was not specific to the study
area and was collected by surveys, and thus subject to non-response
bias after weighting adjustments and recall error. Despite these
limitations, our results were similar to surveys using other specimen
sources [9,11,12,13].
In summary, we performed a serosurvey in Tampa Bay to
determine the prevalence of antibodies to the pH1N1 virus after
the fall wave of the pandemic, and during the early phases of the
pH1N1 vaccination campaign in Florida. We adjusted seroprev-
alence results to account for HI assay specificity and sensitivity and
employed a simple statistical model to estimate the proportion of
seropositivity due to pH1N1 virus infection and vaccination. Our
results provide evidence for substantial immunity against the
pH1N1 virus among the Tampa Bay population. Though disease
activity decreased after December 2009, vaccination levels
continued to increase in Florida; thus the proportion of the
population with immunity to the pH1N1 virus by the end of the
pandemic was probably higher than the estimates presented
herein.
Supporting Information
Appendix S1 Method of seroprevalence adjustment to
account for hemagglutination-inhibition (HI) assay
sensitivity and specificity.
(DOCX)
Appendix S2 Simple statistical model used to estimate
the proportion of seropositive results due to vaccination.
(DOCX)
Table S1 Statistical model to estimate the proportion of
Tampa Bay residents with vaccine-induced pH1N1 virus
seropositivity in November- December 2009, including
all components and equations. 1 Estimated from Behav-
ioral Risk Factors Surveillance System (BRFSS) and National
pH1N1 Flu Survey (NHFS) 2 Vaccine immunogenicity estimates
based on published immunogenicity studies [27,28,29] 3 Esti-
mated proportion of population with vaccine-induced seropositiv-
ity ($1:40 GMT) = (vaccine coverage) x (proportion with $1:40
antibody response) 4 Seroprevalence adjusted for assay sensitiv-
Figure 3. Estimated proportion of the population with pH1N1 virus infection — Tampa Bay, Florida – November-December 2009.
*Estimate of total cumulative incidence is age-standardized.
doi:10.1371/journal.pone.0029301.g003
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adjusted seroprevalence was calculated using a sensitivity of 75%
and a specificity of 97%. For adults aged $ 65 years, assay-
adjusted seroprevalence was calculated using a sensitivity of 75%
and a specificity of 94% [7] 5 Estimated proportion with pH1N1
virus infection prior to vaccination = ([assay adjusted seroprev-
alence] minus [estimated proportion of population with vaccine-
induced seropositivity]) x (estimated proportion of population with
vaccine-induced seropositivity) 6 Proportion with vaccine-in-
duced seropositivity not infected prior to vaccination = (estimated
proportion of population with vaccine-induced seropositivity)
minus (estimated proportion of population with pH1N1 virus
infection prior to vaccination) 7 Proportion infected with pH1N1
virus = (assay-adjusted seroprevalence) minus (proportion with
vaccine-induced seropositivity not infected prior to vaccination).
(DOCX)
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